View Exam | PowerPak

1. Choose the CORRECT statement regarding the regulatory status of marketed veterinary drugs:

A. The marketing status of a veterinary product (prescription vs. OTC) is determined by the FDA based on whether it is possible to prepare “adequate directions for use” under which a layperson can use the drugs safely and effectively. B. Effective January 1, 2017, drugs intended to be added to feeds for food-producing animals will switch from prescription-only status to OTC and no longer will require a veterinarian's order. C. Pharmacists may legally recommend the use of any human-approved OTC product in animals. D. The veterinary prescription legend, “Sold Only Through Licensed Veterinarians,” was placed in federal statute in 1988 through enactment of the Generic Animal Drug and Patent Restoration Act.

2. Which of the following statements regarding the veterinarian–client–patient relationship (VCPR) is correct?

A. The veterinarian and client have entered into an agreement that the client is responsible for care of the animal patient. B. The veterinarian must examine the animal at least once a year to maintain a valid VCPR. C. The veterinarian agrees to be available to personally provide follow-up or make arrangements for patient follow-up. D. Licensed veterinarians employed by Internet pharmacies may legally authorize the use of drugs in animal patients.

3. Which of the following drugs or drug classes is banned from use in racing animals?

A. Corticosteroids. B. Injectable local anesthetics. C. Oxyglobin. D. Procaine.

4. Which of the following types of compounding is most likely to be subject to regulatory action by the FDA?

A. Compounding with bulk drug substances in food animals. B. Compounding outside valid medical need or where no VCPR exists. C. Duplicating a commercially available product. D. Compounding from bulk drugs for use in non-food animals.

5. Which statement regarding regulatory enforcement authority of veterinary drugs is correct?

A. The FDA is the federal agency responsible for enforcement of the Food, Drug, and Cosmetic Act, which governs the safety and effectiveness of “new animal drugs, vaccines, and biologics.” B. The U.S. Department of Agriculture is responsible for ensuring that animal drugs and medicated feeds are safe and effective and that food from treated animals is safe to eat. C. The state boards of veterinary medicine have primary regulatory authority over veterinary practitioners through relevant state veterinary practice acts. D. The Environmental Protection Agency regulates the manufacture, sale, and use of all pesticides, including rodenticides, insecticides, and germicidal preparations used systemically or topically on animals or systemically and topically on inanimate objects.

6. Which statement regarding extra-label use of drugs in animals is correct?

A. “Extra-label” use also is referred to as “conditional” use. B. Veterinary OTC products may legally be used by laypersons in an extra-label fashion. C. Extra-label use of both animal and human drugs is permissible in or on animal feed. D. By legal definition, the term “extra-label” means actual or intended use of a drug in an animal in a manner that is not in accordance with the approved labeling.

7. Which of the following veterinary products is not under FDA jurisdiction?

A. Shampoos for treatment of dermatological diseases. B. Oral insecticides. C. Skin conditioners. D. Topically applied heartworm preventives.

8. Which of the following statements is required to be included in the manufacturer's labeling of a veterinary prescription drug?

A. Rx Only. B. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. C. Caution: Federal law prohibits dispensing this drug without secondary veterinarian authorization. D. Caution: Federal law prohibits the use of this drug in humans.

9. In the Minor Use and Minor Species Act, the term “indexing” refers to:

A. Special incentives for companies to develop veterinary drugs for minor uses or minor species. B. FDA authorization of drugs for use in minor species that are too rare or too varied to be the subject of adequate and well-controlled studies in support of drug approval. C. The ability of companies to legally market a drug after proving that it is safe but before collecting all effectiveness data necessary for full approval, for a limited “index” time (e.g., 5 years). D. The development of threshold numbers that specify the upper limit of minor use for major animal species.

10. A pharmacy that receives a prescription for an animal patient must verify that it represents a legitimate order from an appropriately licensed veterinarian. Which of the following may a pharmacy use routinely for verification?

A. The veterinarian's Drug Enforcement Agency registration number B. The veterinarian's National Provider Identifier number C. The veterinarian's state veterinary license number D. All of these sources may be used for routine verification